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Case Report
Introduction
Adrenocortical carcinoma (ADCC) is generally a rare and
aggressive tumour with a poor prognosis. Surgery should always
be considered when the general condition of the patient permits.
More importantly, early diagnosis and radical surgery offers the
best method of palliation and the only hope of long-term
survival.1 Even in advanced cases when complete resection is not
possible, maximal debulking of the tumour load should be
attempted to allow for maximum benefit of chemotherapy. We
report a 43-year-old Malay man who presented with a large non-
functioning left ADCC extending into the inferior vena cava
(IVC) and right atrium. The ADCC was successfully removed
with the aid of hypothermia and cardiopulmonary bypass.
Case report
A 43-year-old Malay man presented with a 6-month-history of
left flank pain. There was a large mass in the left half of the
abdomen associated with tenderness on deep palpation. The
adrenal hormonal studies were unremarkable. Computerized
tomography (CT) of the abdomen revealed a large, left adrenal
mass measuring 14 x 11 cm with superior pole calcification
(Figure 1). The mass infiltrated the left renal hilum and
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displaced the left kidney inferiorly and anteriorly. Doppler
ultrasound and CT revealed the left renal vein and IVC
thrombosis, with tumour extension into the right atrium.
Echocardiography also showed the tumour thrombus in the
right atrium.
Successful resection of the tumour, left kidney and removal
of its intravascular extension was achieved with the aid of
cardiopulmonary bypass and hypothermia (Figure 2). The
right atrium was opened and the tumour thrombus was
completely removed from the right atrium and another
opening in the IVC. The patient made an uneventful recovery
and was started on mitotane (o,p’-DDD) therapy 1 g twice
daily. At the 6-month follow-up, the patient was well, with no
evidence of tumour recurrence, as confirmed by chest
radiography and CT of the lungs and liver. Nonetheless, he
then ran out of medication and did not continue the adjuvant
therapy. He sought medical attention 4 months later and
had widespread distant metastasis to the lungs; he succumbed
to the cancer 12 months after the radical surgery.
Discussion
The diagnosis of ADCC remains uncommon and, therefore,
leads to non-standardized management. Often, the delay in
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A case of large adrenocortical carcinoma extending into the inferior vena cava and right atrium is reported.
Computed tomography showed a large mass displacing the left kidney inferiorly with an intravascular tumour
thrombus extending into the inferior vena cava and right atrium. Radical surgery under hypothermia and
cardiopulmonary bypass was performed and the tumour mass, together with the tumour thrombus, was
successfully removed. The presence of intravascular tumour extension alone should not be a contraindication to
radical surgical therapy, as it is the best hope for prolonged survival. (Asian J Surg 2003;26(1):40–2)
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presentation, coupled by the unsatisfactory response to
adjuvant therapy, contributes to the dismal outcome. Early
diagnosis and radical surgery appears to be the best method of
palliation and only hope for long-term survival. Nonetheless,
aggressive therapeutic considerations in the management of
ADCC should take a balance between the benefits of radical
surgical intervention and increased potential complications.
Although extension of a tumour thrombus into the IVC is
commonly found in renal cell carcinoma, it is very rare in
ADCC. Such extensive lesions are mostly reported upon
necropsy. Cheung and Thompson were the first to report the
successful removal of a right ADCC with right atrial extension,
using hypothermia and cardiopulmonary bypass.1 Their
patient recovered from the surgery uneventfully and began
mitotane therapy at 3.5 g daily. Of interest, the patient was
disease free for 1 year and then committed suicide for emotional
reasons. This case drew considerable attention to justify such
an aggressive surgical approach.
It certainly seems reasonable to embark on such an
aggressive surgical endeavour to achieve complete surgical
resection to allow for more effective adjuvant mitotane therapy.
Interestingly, anecdotal case reports have shown increased
long-term survival.2–4 On the contrary, others argue against
such an aggressive approach, with great concern for the safety
and outcome of such an undertaking. Furthermore, despite
adequate en bloc radical resection with good surgical margins,
the tumour may still recur. Early recurrence in such cases
points to the overall dismal outcome and prognosis. Conversely,
the poor response to systemic therapy leaves the surgeon with
no other option but en bloc radical resection of the tumour.
Mitotane is considered the drug of choice for patients with
inoperable, recurrent metastatic disease. Following complete
excision of ADCC, adjuvant therapy with mitotane should be
considered to prevent recurrence.5,6 Increased survival and
even long-term remission have been previously reported.7
Nonetheless, because of the rarity of ADCC and in the absence
of randomized controlled studies, others have argued its role
in improving survival.8 Furthermore, the duration and
optimum dosage of maintenance therapy to prevent recurrence
remains to be elucidated. The fact that our patient had tumour
recurrence after he deliberately stopped maintenance therapy
6 months after surgery showed that recurrence was inevitable.
He succumbed to widespread lung metastasis exactly 1 year
after the surgery. Because of this experience, in the absence of
metastasis, it is appropriate to consider such an aggressive
surgical therapy aiming for a complete surgical extirpation of
the tumour to allow for maximum benefit of adjuvant
chemotherapy.
Conclusion
This case illustrates that, in the absence of metastasis,
intravascular tumour extension in ADCCs should not be a
contraindication to surgical intervention.
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